OTCMKTS:SHTDY

Sinopharm Group Competitors

$15.32

+1.14 (+8.04 %)

(As of 04/19/2021 12:00 AM ET)

Add

Compare

Today's Range

$15.18

Now: $15.32▼

$15.35

50-Day Range

$11.25

MA: $12.14▼

$14.18

52-Week Range

$10.20

Now: $15.32▼

$15.35

Volume38,560 shs

Average Volume52,224 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Sinopharm Group (OTCMKTS:SHTDY) Vs. TGIFF, FFNTF, ABSCF, ABAHF, ATTBF, and ACRDF

Should you be buying SHTDY stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Sinopharm Group, including 1933 Industries (TGIFF), 4Front Ventures (FFNTF), AB Science (ABSCF), Abacus Health Products (ABAHF), Abattis Bioceuticals (ATTBF), and Acreage (ACRDF).

Sinopharm Group vs. 1933 Industries Stock

1933 Industries (OTCMKTS:TGIFF) and Sinopharm Group (OTCMKTS:SHTDY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Profitability

This table compares 1933 Industries and Sinopharm Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
1933 Industries	N/A	N/A	N/A
Sinopharm Group	N/A	N/A	N/A

Earnings and Valuation

This table compares 1933 Industries and Sinopharm Group's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
1933 Industries	N/A	N/A	N/A	N/A	N/A
Sinopharm Group	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for 1933 Industries and Sinopharm Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
1933 Industries	0	1	0	0	2.00
Sinopharm Group	0	0	0	0	N/A

Sinopharm Group vs. 4Front Ventures Stock

4Front Ventures (OTCMKTS:FFNTF) and Sinopharm Group (OTCMKTS:SHTDY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and target prices for 4Front Ventures and Sinopharm Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4Front Ventures	0	0	0	0	N/A
Sinopharm Group	0	0	0	0	N/A

Earnings and Valuation

This table compares 4Front Ventures and Sinopharm Group's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4Front Ventures	N/A	N/A	N/A	N/A	N/A
Sinopharm Group	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares 4Front Ventures and Sinopharm Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
4Front Ventures	N/A	N/A	N/A
Sinopharm Group	N/A	N/A	N/A

Sinopharm Group vs. AB Science Stock

Sinopharm Group (OTCMKTS:SHTDY) and AB Science (OTCMKTS:ABSCF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Sinopharm Group and AB Science, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinopharm Group	0	0	0	0	N/A
AB Science	0	0	1	0	3.00

Earnings & Valuation

This table compares Sinopharm Group and AB Science's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinopharm Group	N/A	N/A	N/A	N/A	N/A
AB Science	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Sinopharm Group and AB Science's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sinopharm Group	N/A	N/A	N/A
AB Science	N/A	N/A	N/A

Summary

AB Science beats Sinopharm Group on 1 of the 1 factors compared between the two stocks.

Sinopharm Group vs. Abacus Health Products Stock

Sinopharm Group (OTCMKTS:SHTDY) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Sinopharm Group and Abacus Health Products, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinopharm Group	0	0	0	0	N/A
Abacus Health Products	0	0	0	0	N/A

Earnings & Valuation

This table compares Sinopharm Group and Abacus Health Products' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinopharm Group	N/A	N/A	N/A	N/A	N/A
Abacus Health Products	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Sinopharm Group and Abacus Health Products' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sinopharm Group	N/A	N/A	N/A
Abacus Health Products	N/A	N/A	N/A

Sinopharm Group vs. Abattis Bioceuticals Stock

Sinopharm Group (OTCMKTS:SHTDY) and Abattis Bioceuticals (OTCMKTS:ATTBF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Sinopharm Group and Abattis Bioceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinopharm Group	0	0	0	0	N/A
Abattis Bioceuticals	0	0	0	0	N/A

Earnings & Valuation

This table compares Sinopharm Group and Abattis Bioceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinopharm Group	N/A	N/A	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Sinopharm Group and Abattis Bioceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sinopharm Group	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A

Sinopharm Group vs. Acreage Stock

Sinopharm Group (OTCMKTS:SHTDY) and Acreage (OTCMKTS:ACRDF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Sinopharm Group and Acreage, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinopharm Group	0	0	0	0	N/A
Acreage	0	0	1	0	3.00

Acreage has a consensus target price of $6.00, indicating a potential upside of 133.05%. Given Acreage's higher possible upside, analysts clearly believe Acreage is more favorable than Sinopharm Group.

Earnings & Valuation

This table compares Sinopharm Group and Acreage's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinopharm Group	N/A	N/A	N/A	N/A	N/A
Acreage	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Sinopharm Group and Acreage's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sinopharm Group	N/A	N/A	N/A
Acreage	N/A	N/A	N/A

Summary

Acreage beats Sinopharm Group on 2 of the 2 factors compared between the two stocks.